Torrent Pharmaceuticals Limited has scheduled its 53rd Annual General Meeting (AGM) for June 23, 2026, at 9:30 a.m. via Video Conferencing and Other Audio Visual Means. The meeting will cover the financial year 2025-26, and the company has issued the Notice of AGM and Integrated Annual Report to shareholders. Members holding shares as of the cut-off date, June 16, 2026, are eligible to participate and vote at the meeting.

Pursuant to Regulation 36(1)(a) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Notice and Integrated Annual Report were sent electronically to members with registered email addresses. For shareholders whose email addresses are not registered with the Registrar & Share Transfer Agent or Depository Participants, the company dispatched a letter containing a specific web-link to access the Integrated Annual Report for FY 2025-26.

E-Voting Schedule

The remote e-voting facility is available from 9:00 a.m. on June 19, 2026, until 5:00 p.m. on June 22, 2026. Shareholders who cast their votes during this remote e-voting period are not entitled to vote again during the AGM. However, members who do not participate in remote e-voting may exercise their franchise through the e-voting system during the meeting.

To facilitate the login process for e-voting, the company has outlined requirements for different shareholder categories. Physical shareholders must email their Folio No., name, and self-attested copies of PAN and Aadhaar cards. Demat holders are required to provide their 16-digit beneficiary ID (CDSL) or DP ID plus Client ID (NSDL), along with their name, client master list or statement copy, and self-attested PAN and Aadhaar cards.

Access and Support

The Integrated Annual Report is accessible via the provided web-link and through the Investors section of the company website. Shareholders facing technical difficulties with login via depositories can reach out to the respective helpdesks for assistance.

For general queries regarding the e-voting process, members may refer to the FAQs and e-voting manual available on the CDSL website.

Torrent Pharmaceuticals Limited has filed its Business Responsibility and Sustainability Report (BRSR) for the financial year 2025-26 with BSE Limited and the National Stock Exchange of India Limited. The filing, submitted on June 1, 2026, complies with Regulation 34(2)(f) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The report includes an Independent Reasonable and Limited Assurance Report issued by Grant Thornton Bharat LLP and forms part of the company's Integrated Annual Report for FY 2025-26.

Company Overview and Key Financial Parameters

Torrent Pharmaceuticals, incorporated in 1972 and headquartered in Ahmedabad, reported a standalone turnover of ₹10,498 crore and a net worth of ₹8,452 crore as on March 31, 2026. The company's paid-up capital stands at ₹169.23 crore. Pharmaceutical products account for 100% of its turnover. The company operates 9 national plants, including an R&D unit, and 30 national offices, serving more than 50 international markets through 17 offices.

Workforce and Inclusion Metrics

As at the end of FY 2025-26, the company employed a total of 16,735 employees and 3,606 workers. The workforce composition reflects a predominantly male workforce, with women representing 8% of total employees and 14% of total workers. The Board of Directors comprises 7 members, of whom 2 (29%) are women. Key Managerial Personnel number 4, with no female representation.

ESG Strategy and Double Materiality Assessment

In FY 2025-26, Torrent Pharmaceuticals conducted its first Double Materiality Assessment (DMA), guided by the European Sustainability Reporting Standards (ESRS). The assessment identified material sustainability topics such as Climate Change Adaptation and Mitigation, Resource Management, and Occupational Health & Safety, classifying them by risk or opportunity and financial implication. The Corporate Social Responsibility and Sustainability Committee of the Board oversees sustainability strategy implementation.

Environmental Stewardship and Energy Initiatives

Torrent Pharmaceuticals implemented multiple energy efficiency initiatives in FY 2025-26, including the replacement of chillers at the Indrad facility, saving 77,000 KWH per annum, and the installation of demand-based control for chillers at Dahej, saving 4,40,000 KWH per annum. The company reported a 54% reduction in hazardous waste generation from the base year FY20. A group captive 6.6 MW and 3.3 MW hybrid plant has been approved for installation by FY27. The company has implemented Zero Liquid Discharge (ZLD) mechanisms at its manufacturing facilities and R&D Centre.

Governance, Compliance, and Consumer Responsibility

The company's governance framework includes policies on Business Conduct, Whistle-Blower, Related Party Transactions, and Materiality of Events. During FY 2025-26, no complaints were received related to human rights issues, and no instances of data breaches were reported. The company recorded 3 voluntary product recalls on account of quality issues and 1 forced recall initiated by a regulatory authority. R&D investment as a percentage of total R&D spend stood at 4.62% for FY 2025-26, while Capex investment in environment and social impact technologies stood at 4.63%.

Source: https://lodr-files.dhan.co/lodr-inputs/Company/INE685A01028/9276652ea0524aad.pdf